title: PharmGKB summary: sorafenib pathways.
authors.affiliation: Departments of aBiomedical Data Science bBiomedical Engineering cGenetics Stanford University, Stanford dGilead Sciences, Foster City eEvviva Sciences, San Francisco, California fInova Schar Cancer Institute and Therapeutics, Center for Personalized Health, Falls Church, Virginia, USA.
authors.forename: Li
authors.initials: L
authors.lastname: Gong
authors.forename: Marilyn M
authors.initials: MM
authors.lastname: Giacomini
authors.forename: Craig
authors.initials: C
authors.lastname: Giacomini
authors.forename: Michael L
authors.initials: ML
authors.lastname: Maitland
authors.forename: Russ B
authors.initials: RB
authors.lastname: Altman
authors.forename: Teri E
authors.initials: TE
authors.lastname: Klein
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D053263:Gene Regulatory Networks; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D000071185:Pharmacogenomic Testing; D000071184:Pharmacogenomic Variants; D010671:Phenylurea Compounds / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib